Shweta Bansal1,2, William E Friedrichs1, Chakradhar Velagapudi1,2, Denis Feliers1, Khaled Khazim3, Diane Horn4, John E Cornell5, Sherry L Werner4, Paolo Fanti1. 1. Division of Nephrology, Department of Medicine, University of Texas Health Sciences Center at San Antonio, San Antonio, TX 78229, USA. 2. Renal Section, South Texas Veterans Healthcare System, San Antonio, TX, USA. 3. Faculty of Medicine, Galilee Medical Center, Bar-Ilan University, Safed, Israel. 4. Department of Pathology, University of Texas Health Sciences Center at San Antonio and South Texas Veterans Healthcare System, San Antonio, TX, USA. 5. Department of Epidemiology & Biostatistics, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA.
Abstract
Background: Circulating levels of fibroblast growth factor 23 (FGF23) increase progressively and correlate with systemic inflammation in chronic kidney disease (CKD). The aim of this study was to identify and characterize the causal relationship between FGF23 and inflammation in CKD. Methods: Circulating FGF23 and inflammatory cytokines were correlated in healthy subjects and patients with varying levels of CKD. In addition, FGF23 expression in blood and solid organs was measured in normal mice that were exposed acutely (one time) or chronically (2-week) to low-dose lipopolysaccharide (LPS); chronic exposure being either sustained (subcutaneous pellets), intermittent (daily injections) or combined sustained plus acute (subcutaneous pellets plus acute injection on the day of sacrifice). Blood was analyzed for both terminal (cFGF23) and intact (iFGF23) FGF23 levels. Solid tissues were investigated with immunohistochemistry, enzyme-linked immunosorbent assay and reverse transcription polymerase chain reaction. Results: FGF23 levels correlated significantly with neutrophil gelatinase-associated lipocalin ( r = 0.72, P < 0.001), C-reactive protein ( r = 0.38, P < 0.001), tumor necrosis factor-α ( r = 0.32, P = 0.001) and interleukin-6 ( r = 0.48, P < 0.001). Acute LPS administration increased tissue FGF23 mRNA and plasma levels of cFGF23 but not iFGF23. Neither chronic sustained nor chronic pulsatile LPS increased the tissue or circulating levels of FGF23. However, acute on chronic LPS raised tissue FGF23 mRNA and both circulating cFG23 and iFGF23. Interestingly, the spleen was the major source of FGF23. Conclusion: Acute on chronic exposure to LPS stimulates FGF23 production in a normal mouse model of inflammation. We provide the first evidence that the spleen, under these conditions, contributes substantially to elevated circulating FGF23 levels.
Background: Circulating levels of fibroblast growth factor 23 (FGF23) increase progressively and correlate with systemic inflammation in chronic kidney disease (CKD). The aim of this study was to identify and characterize the causal relationship between FGF23 and inflammation in CKD. Methods: Circulating FGF23 and inflammatory cytokines were correlated in healthy subjects and patients with varying levels of CKD. In addition, FGF23 expression in blood and solid organs was measured in normal mice that were exposed acutely (one time) or chronically (2-week) to low-dose lipopolysaccharide (LPS); chronic exposure being either sustained (subcutaneous pellets), intermittent (daily injections) or combined sustained plus acute (subcutaneous pellets plus acute injection on the day of sacrifice). Blood was analyzed for both terminal (cFGF23) and intact (iFGF23) FGF23 levels. Solid tissues were investigated with immunohistochemistry, enzyme-linked immunosorbent assay and reverse transcription polymerase chain reaction. Results:FGF23 levels correlated significantly with neutrophil gelatinase-associated lipocalin ( r = 0.72, P < 0.001), C-reactive protein ( r = 0.38, P < 0.001), tumor necrosis factor-α ( r = 0.32, P = 0.001) and interleukin-6 ( r = 0.48, P < 0.001). Acute LPS administration increased tissue FGF23 mRNA and plasma levels of cFGF23 but not iFGF23. Neither chronic sustained nor chronic pulsatile LPS increased the tissue or circulating levels of FGF23. However, acute on chronic LPS raised tissue FGF23 mRNA and both circulating cFG23 and iFGF23. Interestingly, the spleen was the major source of FGF23. Conclusion: Acute on chronic exposure to LPS stimulates FGF23 production in a normal mouse model of inflammation. We provide the first evidence that the spleen, under these conditions, contributes substantially to elevated circulating FGF23 levels.
Authors: S Okada; T Yoshida; Z Hong; G Ishii; M Hatano; M Kuro-O; Y Nabeshima; Y Nabeshima; T Tokuhisa Journal: Int Immunol Date: 2000-06 Impact factor: 4.823
Authors: Jair Munoz Mendoza; Tamara Isakova; Ana C Ricardo; Huiliang Xie; Sankar D Navaneethan; Amanda H Anderson; Lydia A Bazzano; Dawei Xie; Matthias Kretzler; Lisa Nessel; L Lee Hamm; Lavinia Negrea; Mary B Leonard; Dominic Raj; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2012-05-03 Impact factor: 8.237
Authors: Rhea Bhargava; Christopher J Altmann; Ana Andres-Hernando; Ryan G Webb; Kayo Okamura; Yimu Yang; Sandor Falk; Eric P Schmidt; Sarah Faubel Journal: PLoS One Date: 2013-11-12 Impact factor: 3.240
Authors: Mark R Hanudel; Brian Czaya; Shirley Wong; Grace Jung; Kristine Chua; Bo Qiao; Victoria Gabayan; Tomas Ganz Journal: Sci Rep Date: 2022-04-23 Impact factor: 4.996
Authors: Stephanie A Bora; Mary J Kennett; Philip B Smith; Andrew D Patterson; Margherita T Cantorna Journal: Front Immunol Date: 2018-03-02 Impact factor: 7.561
Authors: Geoffrey A Block; David P Rosenbaum; Andrew Yan; Peter J Greasley; Glenn M Chertow; Myles Wolf Journal: Nephrol Dial Transplant Date: 2019-02-01 Impact factor: 5.992